Efficacy and safety of olmesartan medoxomil‑amlodipine besylate tablets (Sevikar ® ) in older patients with essential hypertension: Subgroup analysis from the Sevikar study

• Published in: Experimental and therapeutic medicine 2024-02, Vol.27 (2), Article 51
• Main Authors: Cui, Zhaoqiang, Qiu, Zhaohui, Cheng, Wenli, Hu, Wei, Ma, Genshan, Cai, Xiaojun, Jin, Yafei, Zhao, Yi, He, Liqun, Li, Ying, Bu, Peili, Chen, Xiaoping, Wang, Ruxing, Chen, Lin, Dong, Peng, Feng, Liuliu, Han, Xuebin, Hong, Mei, Hou, Yinglong, Liao, Minlei, Wang, Mingliang, Wang, Xiaoyan, Xie, Jianhong, Xu, Yawei, Wang, Zhenxing, Huang, Kai, Li, Yongle, Li, Dongsheng, Ji, Xiaojun, Huang, Jing, Wang, Jun, Fang, Danhong, Wang, Jian'An, Tang, Lijiang, Liu, Yingwu, Fu, Guosheng, Du, Juan, Wang, Ling, Liu, Mengqi, Ge, Junbo
• Format: Article
• Language: English
• Subjects: Aged patients; Amlodipine; Antihypertensives; Blood pressure; Cardiology; Care and treatment; Disease; Dosage and administration; Drug dosages; Drug therapy; Drug therapy, Combination; Essential hypertension; Females; Hypertension; Lipids; Nervous system diseases; Older people; Patient compliance; Patient outcomes; Patient satisfaction; Response rates; Statistical analysis
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2023.12338

Essential hypertension is a notable threat for the older (age, [greater than or equal to] 65 years) population. However, to the best of our knowledge, a real-world study assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablets in older Chinese patients with essential hypertension has not been performed. Therefore, the present study aimed to evaluate the efficacy and safety of OM-AML tablets in these patients. A total of 463 older Chinese patients with essential hypertension treated with OM-AML (20/5 mg) tablets (Sevikar[R]) were analyzed in a prospective, single-arm, multi-center, real-world study. Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, and at week (W)4 and W8 after OM-AML tablet administration were measured. The mean [+ or -] standard error change of SeSBP/SeDBP was -10.3[+ or -]0.8/-4.6[+ or -]0.5 and -12.5[+ or -]0.8/-5.6 [+ or -]0.5 mmHg at W4 and W8, respectively. At W4, 74.1 and 26.8% of patients achieved BP target according to the China and American Heart Association (AHA) criteria, while at W8, 78.0 and 38.7% of patients reached these BP targets accordingly. Finally, 76.5 and 80.5% of patients achieved BP response at W4 and W8, respectively. Furthermore, home-measured SeSBP and SeDBP were significantly decreased from W1 to W8 (both P